,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Dr. Jay R. Luly Ph.D.', 'age': 66, 'title': 'Pres, CEO & Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 1227506, 'exercisedValue': 460721, 'unexercisedValue': 10717033}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
1,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Mr. Paul J. Mellett Jr.', 'age': 67, 'title': 'Sr. VP of Fin. & Admin. and CFO', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 650936, 'exercisedValue': 100863, 'unexercisedValue': 2133748}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
2,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Dr. Yat Sun Or Ph.D.', 'age': 70, 'title': 'Sr. VP of R&D and Chief Scientific Officer', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 720163, 'exercisedValue': 0, 'unexercisedValue': 3573237}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
3,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Mr. Nathaniel S. Gardiner J.D.', 'age': 68, 'title': 'Sr. VP, Gen. Counsel & Sec.', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 657949, 'exercisedValue': 0, 'unexercisedValue': 2323126}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
4,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Dr. Scott T. Rottinghaus M.D.', 'age': 48, 'title': 'Sr. VP & Chief Medical Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 616728, 'exercisedValue': 0, 'unexercisedValue': 0}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
5,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Ms. Jennifer  Viera', 'title': 'Sr. Director of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
6,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Dr. Nathalie  Adda M.D.', 'age': 56, 'title': 'Consultant', 'yearBorn': 1966, 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
7,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Ms. Tara Lynn Kieffer Ph.D.', 'age': 44, 'title': 'Sr. VP of New Product Strategy & Devel.', 'yearBorn': 1978, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
8,500 Arsenal Street,Watertown,MA,02472,United States,617 607 0800,617 607 0530,https://www.enanta.com,Biotechnology,Healthcare,"Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.",160,"{'maxAge': 1, 'name': 'Mr. Brendan  Luu', 'age': 47, 'title': 'Sr. VP of Bus. Devel.', 'yearBorn': 1975, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",3,4,4,8,5,1693526400,1672444800,86400,2,13.23,13.1,12.46,13.3,13.23,13.1,12.46,13.3,0.0,0.40491,-1.8887241,4697458,4697458,376332,1201400,1201400,12.75,12.76,900,800,268035232,11.56,62.06,3.325953,16.6613,33.534775,0.0,0.0,USD,-89425856,-1.6386501,15736800,21055400,1682709,1435354,1690761600,1693440000,0.0799,0.06542,0.95369005,7.46,0.1031,11.295,1.1270473,1664496000,1696032000,1688083200,-132057000,-5.76,-6.74,-1.11,0.683,NMS,EQUITY,ENTA,ENTA,"Enanta Pharmaceuticals, Inc.","Enanta Pharmaceuticals, Inc.",1363872600,America/New_York,EDT,-14400000,12.73,48.0,14.0,30.22,25.0,2.6,hold,9,386584992,18.36,-130868000,29124000,6.326,6.577,80589000,12.246,3.857,-0.18916,-0.45866,86160000,-22698750,-97086000,-0.03,1.0,-1.62389,-1.65314,USD,
